# A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

> **NCT01214993** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 38 (actual)

## Conditions studied

- Infections, Human Immunodeficiency Virus and Tuberculosis

## Interventions

- **DRUG:** GSK1349572
- **DRUG:** Placebo
- **DRUG:** Iohexol Injection
- **DRUG:** Para-aminohippurate infusion

## Key facts

- **NCT ID:** NCT01214993
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2012-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214993, "A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01214993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*